Here are the Form 4 insider transactions from X4 Pharmaceuticals, Inc. (XFOR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XFOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XFOR filings page.
X4 Pharmaceuticals, Inc. Executive Chairman and director Adam R. Craig directly purchased 4,600 shares of common stock on October 16, 2026, at $2.5834 per share. His reported direct position after the purchase was 333,251 shares; of the reported common-stock position, 193,254 shares represent restricted stock units. No Rule 10b5-1 plan is reported.
X4 Pharmaceuticals, Inc. Chief Financial Officer David Kirske reported selling 11,767 shares of common stock on October 1, 2026, at a weighted average price of $2.8604 per share. The sale covered a personal income tax obligation upon settlement of a restricted stock unit award. No Rule 10b5-1 plan is reported. His reported holdings afterward were 155,983 shares, including 64,418 shares that represent restricted stock units.
X4 Pharmaceuticals, Inc. president John Volpone reported selling 24,576 shares of common stock on August 12, 2026 at a weighted average price of $4.44 per share, in transactions ranging from $4.33–$4.55, to cover a personal income tax obligation upon settlement of a restricted stock unit award. Following these sales, he directly holds 265,305 shares, of which 193,254 shares represent restricted stock units.
X4 Pharmaceuticals, Inc. Executive Chairman Adam R. Craig reported selling 47,436 shares of common stock on August 12, 2026 in an open-market transaction at a weighted average price of $4.4445 per share, with individual trade prices ranging from $4.33 to $4.55. According to the disclosure, the sale was made to cover personal income tax obligations arising from the settlement of a restricted stock unit award. Following this transaction, Craig directly held 328,651 shares of common stock, including 193,254 shares represented by restricted stock units.
X4 Pharmaceuticals Chief Financial Officer David Kirske sold 8,543 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $4.2641 per share, in multiple trades between $4.21 and $4.31.
According to the filing, the sale was made to cover a personal income tax obligation arising from the settlement of a restricted stock unit award. After this transaction, Kirske directly owns 167,750 shares of X4 Pharmaceuticals common stock, including 96,627 shares represented by restricted stock units.
X4 Pharmaceuticals director Kelly Gold received a stock option grant as part of compensation. The award covers 110,000 shares of common stock with an exercise price of $4.085 per share and expires on July 1, 2036. According to the disclosure, these options were granted at no cost on the grant date and will vest in full on the one-year anniversary of the grant date, as long as Gold continues providing services through that date. Following this award, Gold is reported to hold stock options covering 110,000 shares directly.
X4 Pharmaceuticals Chief Financial Officer David Kirske reported an open-market sale of common stock. On May 12, 2026, he sold 16,961 shares of X4 Pharmaceuticals stock at a weighted average price of $4.2934 per share. According to the footnotes, this sale was made to cover a personal income tax obligation arising from the settlement of a restricted stock unit award, making it a largely tax-driven transaction rather than a discretionary portfolio move. After the sale, Kirske directly owned 176,293 shares, of which 128,836 shares are in the form of restricted stock units, so he continues to hold a substantial equity stake in the company.
X4 Pharmaceuticals director Bridger Gary received a new stock option grant. On 01/01/2026, he was awarded options to purchase 110,000 shares of X4 Pharmaceuticals common stock at an exercise price of $4.00 per share, expiring on 01/01/2036.
The options will vest in full only if stockholders approve an increase in the share reserve under the company’s Amended and Restated 2017 Equity Incentive Plan at the company’s 2026 annual meeting of stockholders, and if he continues providing services through that date. This filing reports an equity-based compensation grant rather than a share sale.